Three tickers for capital gains

On December 13, 2022, a Big Pharma giant quietly bought one AI-designed drug for $4 billion.   That makes it the biggest deal for an AI-designed drug in history.   But very few people even know about it...yet.   Even leading investors in the U.S. have no idea.   And they don't know that this tiny AI-biotech designed the drug.   But this won't stay quiet much longer.   On January 9, 2023, Bristol Myers Squibb signed a $2.7 billion deal to have their AI-platform develop six new drugs.   On October 6, 2022, Eli Lilly signed a $425 million deal to have their AI-platform develop a new drug.   These seven drugs alone could bring $28 billion to this little-known company.   That doesn't include deals they signed with Sanofi, Nimbus Therapeutics, Petra Pharma and others.   Wall Street doesn't yet grasp how this company is quietly revolutionizing the drug discovery business...   Which is why I believe this will be the biggest AI winner you never heard of.   Get the name of the stock here...while it's still a small-cap >>>   "The Buck Stops Here,"     This editorial email containing advertisements was sent to diansastroxz.forex@blogger.com because you subscribed to this service. To stop receiving these emails, click here.   OpportunisticInvestor.Net welcomes your feedback and questions. But please note: The law prohibits us from giving personalized advice.   © OpportunisticInvestor.Net. All rights reserved. Any reproduction, copying, or redistribution of our content, in whole or in part, is prohibited without written permission.   4395 Fulton Industrial Blvd SW, Ste D #114, Atlanta, GA 30336, United States